Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.76 USD | +1.34% | -1.73% | +18.91% |
31/05 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
31/05 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.91% | 2.06B | C | ||
-3.17% | 8.22B | B- | ||
+6.11% | 5.72B | B | ||
+31.98% | 5.67B | C | ||
-10.03% | 4.11B | C | ||
-59.94% | 2.68B | D+ | ||
+11.23% | 2.68B | - | - | |
-5.14% | 2.37B | B- | ||
-7.56% | 1.8B | D+ | ||
+3.07% | 1.6B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYGN Stock
- Ratings Myriad Genetics, Inc.